Due to recent events, i have beone radical af. I hate islam. I hate most blacks.
6
At #EHA26, a real‑world poster analysis examined treatment discontinuation with covalent BTK inhibitors in first‑line #CLL.
See the full presentation on the BeOne Medical website: bit.ly/3Qp9RCK
41
A comparative analysis presented at #EHA26 explored BTK inhibitor therapy in untreated CLL and considerations for fixed‑duration outcome interpretation.
Explore the full presentation on the BeOne Medical website: bit.ly/4etB4NI
37
At #EHA26, a SEQUOIA subgroup analysis poster reported long‑term safety and efficacy outcomes with a BTK inhibitor in treatment‑naïve CLL/SLL patients aged ≥80 years.
Learn more on the BeOne Medical website: bit.ly/4e0UsjG
1
33
At #EHA26, we presented a real‑world analysis examining the impact of atrial fibrillation on cardiovascular outcomes and healthcare resource utilization among patients with #CLL.
Additional information is available on the BeOne Medical website: bit.ly/4uoxcT1
19
At #EHA26, a phase 1 poster reported results from an ADME and drug–drug interaction study evaluating CYP3A‑mediated interaction potential for a BTK degrader.
Learn more on the BeOne Medical website: bit.ly/4uZj1Fh
20
Phase 1 poster results from the CaDAnCe‑101 study were presented at #EHA26, evaluating a BTK degrader in BTK inhibitor–naive #CLL/SLL and other B‑cell malignancies.
See the full presentation on the BeOne Medical website: bit.ly/4v2MTQY
1
32
At #EHA26, we presented a phase 1 poster update evaluating a BTK degrader in patients with relapsed/refractory Waldenström macroglobulinemia.
Explore the presentation on the BeOne Medical website: bit.ly/4xh7IcX
28